Running Title: Inebilizumab pharmacodynamic modeling and exposure-response assessment
Li Yan1*, Bing Wang2, Dewei She1, Ben Mitchel2, Ryan Criste2, Daniel Cimbora1, Eliezer Katz1 and William A Rees1
1Horizon Therapeutics, Gaithersburg, MD, USA;2Amador Bioscience, Pleasanton, CA, USA